FDA committees say keep rosiglitazone available but increase warnings
AUTOR(ES)
Tanne, Janice Hopkins
FONTE
BMJ Publishing Group Ltd.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1939771Documentos Relacionados
- FDA moves to highlight warnings about HRT
- FDA advisory panel calls for suicide warnings over new antidepressants
- FDA issues warnings about drugs used to treat fungal nail infections
- FDA calls for warnings on anaemia drugs amid reports of incentives to doctors
- FDA will increase postmarketing surveillance of drugs